An analysis of matched tumor-normal samples from dozens of colorectal cancer patients pointed to microbiome differences related to mutations and other tumor features.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The company presented a poster at the ACG meeting this week that reported over 80 percent sensitivity in a retrospective cohort with a majority of early-stage cancers.
Researchers found relevant non-coding mutations in colorectal cancer cell lines by systematically profiling chromosome interactions at promoter fragments.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
